PRISM MediaWire

Medical Devices

Establishment Labs Holdings (ESTA) Nearly Doubles Share Price Following Debut on PRISM Women’s Health Index Two Months Ago

New York, N.Y., February 29, 2024 - PRISM MediaWire - Establishment Labs Holdings Inc. (ESTA) surged by 24% today, continuing its upward trajectory that began at the onset of the year. Included in the PRISM Women’s Health Index since its inauguration on January 4th, the ...

29 February 2024

Artificial Intelligence:

"LivePerson, Inc. Shares Plummet 42% Following Q4 Loss and Missed Estimates

New York, N.Y., February 29, 2024 - PRISM MediaWire - LivePerson, Inc. (NASDAQ: LPSN) is currently experiencing significant challenges, evident in its impact on the PRISM NextGen Tech & AI Index where it stands as the largest detractor, causing a notable decline of a...

29 February 2024

Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...

29 February 2024

Electric Vehicles

Polestar Automotive Secures $950 Million in Funding Amid Business Plan Progress

New York, N.Y., February 29, 2024 - PRISM MediaWire - Polestar Automotive Holding UK PLC (Nasdaq: PSNY) has recently announced the successful acquisition of $950 million through a three-year loan facility facilitated by a consortium of 12 prominent international banks, w...

29 February 2024

PRISM MarketView

Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

New York, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in generali...

29 February 2024

PRISM MarketView

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million ...

29 February 2024

PRISM MarketView

Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs.

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenu...

28 February 2024

PRISM MarketView

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024